Differential effects of epsilon-aminocaproic acid and aprotinin on matrix metalloproteinase release in patients following cardiopulmonary bypass

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 4, 2008, Pages 418-423

  Dorman, Bruce H ^a   Stroud, Robert E ^a   Wyckoff, Michael M ^b   Zellner, James L ^b   Botta, Don ^b   Leonardi, Amy H ^a   Ikonomidis, John S ^a   Spinale, Francis G ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Memorial Hospital   (United States)

^c Strom Thurmond Research Center   (United States)

Author keywords

Aprotinin; Cardiac surgery; Epsilon aminocaproic acid; Interleukins; Matrix metalloproteinases

Indexed keywords

AMINOCAPROIC ACID; APROTININ; GELATINASE B; INTERLEUKIN 6; NEUTROPHIL COLLAGENASE;

ADULT; ANESTHESIA INDUCTION; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; ENZYME RELEASE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

6-AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD LOSS, SURGICAL; CARDIOPULMONARY BYPASS; FEMALE; HUMANS; INTERLEUKINS; INTRAOPERATIVE COMPLICATIONS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SERINE PROTEINASE INHIBITORS;

EID: 42449095077     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318168400a     Document Type: Article

References (39)

1. Spinale FG. Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
2. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92:827-839.
3. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2006;69:614-624.
4. Li J, Schwimmbeck PL, Tschope C, et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res. 2002;56: 235-247.
5. Wilson EM, Moainie SL, Baskin JM, et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation. 2003;107:2857-2863.
6. Sluijter JP, Pulskens WP, Schoneveld AH, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006;37:235-239.
7. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001;104:1899-1904.
8. Barbour JR, Spinale FG, Ikonomidis JS. Proteinase systems and thoracic aortic aneurysm progression. J Surg Res. 2007;139:292-307.
9. Mukherjee R, Brinsa TA, Dowdy KB, et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107:618-625.
10. Webb CS, Bonnema DD, Ahmed SH, et al. Specific temporal profile of matrix metalloproteinase release occurs in patients following myocardial infarction: relation to left ventricular remodeling. Circulation. 2006;114: 1020-1027.
11. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/ tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional & clinical manifestations of hypertensive heart disease. Circulation. 2006;113: 2089-2096.
12. Joffs C, Gunasinghe HR, Multani MM, et al. Cardiopulmonary bypass induces the synthesis and release of matrix metalloproteinases. Ann Thorac Surg. 2001;71:1518-1523.
13. Mayers I, Hurst T, Puttagunta L, et al. Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in human hearts. J Thorac Cardiovasc Surg. 2001;122:746-752.
14. Lin TC, Li CY, Tsai CS, et al. Neutrophil-mediated secretion and activation of matrix metalloproteinase-9 during cardiac surgery with cardiopulmonary bypass. Anesth Analg. 2005;100:1554-1560.
15. Galley HF, Macaulay GD, Webster NR. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and tumour necrosis factor alpha release during cardiopulmonary bypass. Anaesthesia. 2002;57:659-662.
16. Deschamps AM, Spinale FG. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006;69:666-676.
17. Rutschow S, Li J, Schultheiss HP, et al. Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res. 2006;69: 646-656.
18. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, et al. Is E-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? Circulation. 1999;99:81-89.
19. van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 1987;44:640-645.
20. Royston D, Bidstrup BP, Taylor KM, et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2:1289-1291.
21. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in a coronary arterty bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128:442-448.
22. Slaughter TF, Faghih F, Greenberg CS, et al. The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg. 1997;85:1221-1226.
23. Mojcik CF, Levy JH. Aprotinin and the systematic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg. 2001;71:745-754.
24. Landis RC, Haskard DO, Taylor KM. New anti-inflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg. 2001;72: S1808-S1813.
25. Bull D, Connors R, Albanil A, et al. Cardiopulmonary support and physiology. Aprotinin preserves myocardial biochemical function during cold storage through suppression of tumor necrosis factor. J Thorac Cardiovasc Surg. 2000;119:242-250.
26. Greilich PE, Brouse CF, Rinder CS, et al. Effects of E-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology. 2004;100:1-17.
27. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007;115:2801-2813.
28. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. NEJM. 2006;354:353-365.
29. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999;354:1940-1947.
30. Greilich PE, Okada K, Latham P, et al. Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and epsilon-aminocaproic acid. Circulation. 2001;104:I265-I269.
31. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 92: 827-839, 2003.
32. Pugin J, Widmer MC, Kossodo S, et al. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol. 1999;20:458-464.
33. Gioia M, Fasciglione GF, Marini S, et al. Modulation of the catalytic activity of neutrophil collagenase MMP-8 on bovine collagen I. Role of the activation cleavage and of the hemopexin-like domain. J Biol Chem. 2002;277:23123-23130.
34. Frake PC, Smith HE, Chen LF, et al. Prestorage leukoreduction prevents accumulation of matrix metalloproteinase 9 in stored blood. Arch Surg. 2006;141:396-400; discussion, 400.
35. Beath SM, Nuttall GA, Fass DN, et al. Plasma aprotinin concentrations during cardiac surgery: full- versus half-dose regimens. Anesth Analg. 2000;91:257-264.
36. Toy LW. Matrix metalloproteinases: their function in tissue repair. J Wound Care. 2005;14:20-22.
37. Steffensen B, Hakkinen L, Larjava H. Proteolytic events of wound-healing-coordinated interactions among matrix metalloproteinases (MMPs), integrins, and extracellular matrix molecules. Crit Rev Oral Biol Med. 2001;12:373-398.
38. Furnary AP, Wu Y, Hiratzka LF, et al. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation. 2007;116(Suppl 11):I127-I133.
39. American Heart Association Advisory: Bayer suspends marketing of aprotinin (Trasylol) at FDA request. November 2007 Available at: http://www.informz.net/heart/archives/archive_518051.html.